PK-PD Therapy Ranking Using Patient-Specific Anti-Infective Models

The patent introduces a computer-based system as an intermediary between clinical decision-making and pharmacokinetic-pharmacodynamic target attainment estimation. This intermediary automatically performs complex calculations using population pharmacokinetic models, simulation methodologies, and patient-specific factors (such as pathogen MIC, drug exposure, and demographic information) to generate probability estimates of PK-PD target attainment. By delegating these computationally intensive tasks to the computer-based system, the patent achieves high measurement precision without requiring clinicians to directly manage the underlying complexity of pharmacokinetic modeling and simulation.

The computer-based system is designed to universally process multiple types of patient-specific factors through a single integrated platform. It simultaneously handles pathogen minimum inhibitory concentration (MIC) data, drug exposure information, demographic characteristics, and other relevant clinical parameters. The system applies population pharmacokinetic models and simulation methodologies that can accommodate diverse input types, converting them into a unified probability estimate of PK-PD target attainment. This multi-functional approach enables reliable treatment outcome predictions while consolidating the complexity of collecting and measuring multiple patient-specific factors into a single automated system.